PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, ...

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of ...

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

-- 11 new abstracts including MASH data to be presented at the 76th Annual AASLD The Liver Meeting (R), 7-11 November -- Highlights include data from post-hoc analyses of the ESSENCE trial ...

MASH data to be presented at the 76th Annual AASLD The Liver Meeting®, 7-11 November Highlights include data from post-hoc analyses ...